Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Director Richard Douglas purchased 10,000 shares of the company’s stock in a transaction on Thursday, September 12th. The shares were purchased at an average price of $6.03 per share, for a total transaction of $60,300.00. Following the purchase, the director now owns 70,000 shares in the company, valued at approximately $422,100. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Richard Douglas also recently made the following trade(s):
- On Tuesday, September 10th, Richard Douglas purchased 20,000 shares of Aldeyra Therapeutics stock. The shares were purchased at an average price of $5.00 per share, for a total transaction of $100,000.00.
NASDAQ ALDX opened at $5.76 on Monday. The stock has a market capitalization of $161.33 million, a price-to-earnings ratio of -3.22 and a beta of 0.61. Aldeyra Therapeutics, Inc has a twelve month low of $4.31 and a twelve month high of $16.70. The stock has a 50-day moving average of $5.05 and a 200 day moving average of $6.80.
Several institutional investors have recently made changes to their positions in the business. Rhumbline Advisers raised its holdings in shares of Aldeyra Therapeutics by 17.3% during the first quarter. Rhumbline Advisers now owns 27,183 shares of the biotechnology company’s stock valued at $245,000 after acquiring an additional 4,010 shares during the last quarter. BNP Paribas Arbitrage SA acquired a new position in shares of Aldeyra Therapeutics during the first quarter valued at approximately $40,000. Strs Ohio raised its holdings in shares of Aldeyra Therapeutics by 7.5% during the second quarter. Strs Ohio now owns 71,900 shares of the biotechnology company’s stock valued at $431,000 after acquiring an additional 5,000 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Aldeyra Therapeutics during the second quarter valued at approximately $30,000. Finally, Bank of New York Mellon Corp raised its holdings in shares of Aldeyra Therapeutics by 7.7% during the second quarter. Bank of New York Mellon Corp now owns 75,353 shares of the biotechnology company’s stock valued at $452,000 after acquiring an additional 5,406 shares during the last quarter. 61.26% of the stock is owned by institutional investors and hedge funds.
ALDX has been the topic of several research analyst reports. Cantor Fitzgerald set a $33.00 price target on Aldeyra Therapeutics and gave the company a “buy” rating in a research note on Tuesday, June 25th. Zacks Investment Research downgraded Aldeyra Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 14th. Finally, ValuEngine raised Aldeyra Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, September 10th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $26.79.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.
Featured Article: How to execute a trade ex-dividend strategy?
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.